Search

Your search keyword '"Glioblastomas -- Care and treatment"' showing total 75 results
Start Over Descriptor "Glioblastomas -- Care and treatment" Topic clinical trials
75 results on '"Glioblastomas -- Care and treatment"'

2. I-Mab, Genexine receive China NMPA nod to begin phase 2 trial of TJ107/HyLeukin-7 in glioblastoma multiforme

Subjects
Clinical trials, Glioblastomas -- Care and treatment, Medical supplies, Interleukins, Gliomas, Respiratory system agents, Backup software, Biotechnology industries, Pharmaceuticals and cosmetics industries
Abstract

I-Mab, a clinical-stage biopharmaceutical company, and Genexine, a clinical-stage biotechnology company, announced that the China National Medical Products Administration (NMPA) has cleared the initiation of a phase 2 clinical trial [...]

Published
2020

3. Medicenna Therapeutics completes enrollment in phase 2b study of MDNA55 to treat recurrent glioblastoma

Subjects
Clinical trials, Brain tumors -- Care and treatment, Glioblastomas -- Care and treatment, Brain cancer, Chairpersons, Gliomas, Pharmaceuticals and cosmetics industries
Abstract

Medicenna Therapeutics Corp., a clinical stage immuno-oncology company, announced that it has completed enrollment in the phase 2b clinical study of MDNA55 for the treatment of recurrent glioblastoma (rGBM), the [...]

Published
2019

4. New Glioblastomas Study Findings Have Been Reported by Investigators at University Hospital [Lomustine-temozolomide Combination Therapy Versus Standard Temozolomide Therapy In Patients With Newly Diagnosed Glioblastoma With Methylated Mgmt ...]

Subjects
Medical care quality, Temozolomide -- Standards, Physical fitness, Methylation, Glioblastomas -- Care and treatment, Lomustine, Obesity, Radiotherapy, Antineoplastic agents, Gliomas, Clinical trials, Managers, Editors, Health
Abstract

2019 MAR 16 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Oncology - Glioblastomas have been published. According to [...]

Published
2019

5. Vaximm begins phase I/II trial with VXM01 oral T-cell immunotherapy in combo with Avelumab in glioblastoma

Subjects
Merck KGaA -- Product development -- Planning, Pfizer Inc. -- Product development -- Planning, Pharmaceutical industry -- Product development -- Planning, T cells, Clinical trials, Immunotherapy, Glioblastomas -- Care and treatment, Biotechnology industries, Labels, Biotechnology, Recurrence (Disease), Gliomas, Antibodies, Company business planning, Pharmaceuticals and cosmetics industries
Abstract

Vaximm AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, announced that the first patient has been dosed in a phase I/II trial evaluating VXM01 oral immunotherapy in [...]

Published
2018

6. Aivita Biomedical gets US FDA nod to begin phase II trial of ROOT OF CANCER technology in patients with glioblastoma multiforme

Subjects
United States. Food and Drug Administration, Clinical trials, Cancer treatment, Cancer -- Care and treatment, Medical research, Stem cells, Cancer patients -- Care and treatment, Ovarian cancer -- Care and treatment, Glioblastomas -- Care and treatment, Pharmaceuticals and cosmetics industries
Abstract

Aivita Biomedical, a biotech company specializing in innovative stem cell applications, announced the US Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for a phase [...]

Published
2018

7. Findings in the Area of Alkylating Agents Reported from Mayo Clinic (Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02)

Subjects
Clinical trials, Physical fitness, Radiotherapy, Radiation (Physics), Glioblastomas -- Care and treatment, Health
Abstract

2018 MAY 5 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Researchers detail new data in Drugs and Therapies - Alkylating Agents. According [...]

Published
2018

8. First Patient Enrolled in Novocures Global Phase 3 TRIDENT Trial of Optune Concurrent with Radiation Therapy in Newly Diagnosed Glioblastoma

Subjects
Clinical trials, Alternating electric field therapy, Radiotherapy, Radiation (Physics), Glioblastomas -- Care and treatment, Business, international, Law, Optune (Medical instrument) -- Product development
Abstract

Novocure (NASDAQ: NVCR) today announced the first patient has been enrolled in its global phase 3 TRIDENT trial, a randomized study in newly diagnosed glioblastoma (GBM) testing the potential survival [...]

Published
2020

9. First Patient Enrolled in Novocure's Global Phase 3 TRIDENT Trial of Optune[R] Concurrent with Radiation Therapy in Newly Diagnosed Glioblastoma

Subjects
Clinical trials, Alternating electric field therapy, Radiotherapy, Radiation (Physics), Glioblastomas -- Care and treatment, Business, Business, international, Optune (Medical instrument) -- Product development
Abstract

TRIDENT will test the potential survival benefit of initiating Optune concurrent with radiation therapy in patients with newly diagnosed glioblastoma Preclinical studies demonstrate that Tumor Treating Fields increase sensitivity to [...]

Published
2020

10. AIVITA Biomedical's Phase 2 Glioblastoma Trial Shows Improved Progression Free Survival

Subjects
Clinical trials, Cancer vaccines -- Product development, Stem cells, Glioblastomas -- Care and treatment, Business, international, Law
Abstract

AIVITA Biomedical, Inc., a private biotechnology company specializing in innovative stem cell applications, today announced data from its multi-center Phase 2 clinical trial of its personalized cancer vaccine, AV-GBM-1, in [...]

Published
2020

11. AIVITA Biomedical's Phase 2 Glioblastoma Trial Shows Improved Progression Free Survival

Subjects
Clinical trials, Cancer vaccines -- Product development, Stem cells, Glioblastomas -- Care and treatment, General interest, News, opinion and commentary
Abstract

IRVINE: AIVITA Biomedical, Inc. has issued the following news release: AIVITA Biomedical, Inc., a private biotechnology company specializing in innovative stem cell applications, today announced data from its multi-center Phase [...]

Published
2020

12. BerGenBio ASA: BERGENBIO ANNOUNCES FIRST PATIENT DOSED IN RECURRENT GLIOBLASTOMA INVESTIGATOR SPONSORED PHASE I|II STUDY ASSESSING SELECTIVE AXL INHIBITOR BEMCENTINI

Subjects
United States. National Cancer Institute, Clinical trials, Medical research, Glioblastomas -- Care and treatment, General interest, News, opinion and commentary, The University of Alabama at Birmingham
Abstract

Oslo: BerGenBio ASA has issued the following news release: BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces that [...]

Published
2020

13. Bergenbio Announces First Patient Dosed in Recurrent Glioblastoma Investigator Sponsored Phase I|II Study Assessing Selective AXL Inhibitor Bemcentinib

Subjects
United States. National Cancer Institute, Clinical trials, Medical research, Glioblastomas -- Care and treatment, General interest, News, opinion and commentary, The University of Alabama at Birmingham
Abstract

BERGEN: BerGenBio ASA has issued the following news release: BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces that [...]

Published
2020

14. Bergenbio Announces First Patient Dosed in Recurrent Glioblastoma Investigator Sponsored Phase I|II Study Assessing Selective AXL Inhibitor Bemcentinib

Subjects
United States. National Cancer Institute, Clinical trials, Medical research, Glioblastomas -- Care and treatment, Business, international, Law, The University of Alabama at Birmingham
Abstract

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces that the first patient has been dosed and continues on [...]

Published
2020

15. Ziopharm Oncology Completes Enrollment of Phase 2 Trial Evaluating Controlled IL-12 in Combination with Libtayo(R) in Patients with Glioblastoma

Subjects
Clinical trials, Cancer treatment, Hospitals, Glioblastomas -- Care and treatment, Banking, finance and accounting industries, Business, Libtayo (Medication) -- Product development
Abstract

BOSTON, June 22, Jun 22, 2020 (GLOBE NEWSWIRE via COMTEX) -- Ziopharm Oncology, Inc. ('Ziopharm' or 'the Company') (Nasdaq:ZIOP) today announced that 36 subjects have been enrolled in the phase [...]

Published
2020

16. Karyopharm Announces Dosing of First Patient in a Phase 1|2 Study of Selinexor in Combination with Standard of Care Therapy for Patients with Newly Diagnosed or Recurrent Glioblastoma

Subjects
United States. Food and Drug Administration -- Standards -- International economic relations, Clinical trials, Cellular proteins -- Standards, Medical research, Glioblastomas -- Care and treatment, Gliomas, Proteins, Pharmaceutical industry, Cancer, Tumors, Business, international, Law, Xpovio (Medication)
Abstract

(GlobeNewswire) - Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced dosing of the first patient in a Phase 1/2 clinical study evaluating oral selinexor in combination with standard [...]

Published
2020

17. Karyopharm Announces Dosing of First Patient in a Phase 1/2 Study of Selinexor in Combination with Standard of Care Therapy for Patients with Newly Diagnosed or Recurrent Glioblastoma

Subjects
United States. Food and Drug Administration -- Standards -- International economic relations, Clinical trials, Cellular proteins -- Standards, Medical research, Glioblastomas -- Care and treatment, Gliomas, Proteins, Pharmaceutical industry, Tumors, Banking, finance and accounting industries, Business, Xpovio (Medication)
Abstract

NEWTON, Jun 09, 2020 (GLOBE NEWSWIRE via COMTEX) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced dosing of the first patient in a Phase 1/2 clinical study [...]

Published
2020

18. China NMPA Approves Optune[R] for the Treatment of Newly Diagnosed and Recurrent Glioblastoma

Subjects
Zai Lab Ltd., Alternating electric field therapy, Chemotherapy, Pharmaceutical industry, Glioblastomas -- Care and treatment, Medical supplies, Cancer treatment, Gliomas, Cancer, Clinical trials, Tumors, Business, Business, international, Optune (Medical instrument)
Abstract

Optune is the first innovative treatment for glioblastoma approved in China in over 15 years A large, global phase 3 pivotal clinical study in newly diagnosed glioblastoma showed adding Optune [...]

Published
2020

19. China NMPA Approves Optune(R) for the Treatment of Newly Diagnosed and Recurrent Glioblastoma

Subjects
Zai Lab Ltd., Cancer treatment, Alternating electric field therapy, Pharmaceutical industry, Glioblastomas -- Care and treatment, Chemotherapy, Gliomas, Cancer, Clinical trials, Tumors, Banking, finance and accounting industries, Business, Optune (Medical instrument)
Abstract

SHANGHAI and ST. HELIER, Jersey, May 13, 2020 (GLOBE NEWSWIRE via COMTEX) -- Optune is the first innovative treatment for glioblastoma approved in China in over 15 years A large, [...]

Published
2020

20. MGC Pharmaceuticals Ltd: Successful research results for MGC cannabinoid formulation on one of the most aggressive cancers, glioblastoma

Subjects
Cancer -- Care and treatment, Cancer research -- Behavior, Brain tumors -- Care and treatment, Glioblastomas -- Care and treatment, Stem cell research, Seeds, Neurosurgery, Pharmaceutical industry, Clinical trials, Novels, General interest, News, opinion and commentary
Abstract

Sydney, Australia: MGC Pharmaceuticals Ltd has issued the following news release: MGC Pharmaceuticals Ltd (ASX: MXC, 'MGC' or 'the Company'), a European based 'Seed to Medicine' bio-pharma company specialising in [...]

Published
2020

22. Diffusion Pharmaceuticals Reports Favorable Safety Data for Dose-Escalation Run-in of Phase 3 INTACT Study in Glioblastoma Multiforme Patients

Subjects
Clinical trials, Medical research, Glioblastomas -- Care and treatment, Gliomas, Data security, Banking, finance and accounting industries, Business
Abstract

CHARLOTTESVILLE, Jul 23, 2019 (GLOBE NEWSWIRE via COMTEX) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions, today reported that based on [...]

Published
2019

23. Ziopharm Oncology Initiates Phase 2 Trial Evaluating Combination Therapy of Controlled IL-12 with Libtayo(r) (cemiplimab-rwlc) to Treat Patients with Recurrent Glioblastoma

Subjects
Clinical trials, Cancer treatment, Interleukins -- Product development, Nivolumab, Glioblastomas -- Care and treatment, Antibodies, Gliomas, Advertising executives, Hospitals, General interest, News, opinion and commentary, Libtayo (Medication)
Abstract

BOSTON : ZIOPHARM Oncology Inc has issued the following press release: Ziopharm Oncology, Inc. ('Ziopharm' or 'the Company') (Nasdaq:ZIOP) today announced the initiation of a phase 2 clinical trial evaluating [...]

Published
2019

24. Ziopharm Oncology Initiates Phase 2 Trial Evaluating Combination Therapy of Controlled IL-12 with Libtayo(R) (cemiplimab-rwlc) to Treat Patients with Recurrent Glioblastoma

Subjects
United States. Food and Drug Administration, Clinical trials, Cancer treatment, Interleukins -- Product development, Nivolumab, Advertising executives, Glioblastomas -- Care and treatment, Antibodies, Gliomas, Cancer, Hospitals, Banking, finance and accounting industries, Business
Abstract

BOSTON, June 27, Jun 27, 2019 (GLOBE NEWSWIRE via COMTEX) -- Ziopharm Oncology, Inc. ('Ziopharm' or 'the Company') (Nasdaq:ZIOP) today announced the initiation of a phase 2 clinical trial evaluating [...]

Published
2019

25. OncoSynergy Announces FDA Acceptance of IND Application for Phase I Trial of OS2966 in Patients with Recurrent Glioblastoma

Subjects
United States. Food and Drug Administration, Clinical trials, Recurrence (Disease) -- Care and treatment, Brain tumors -- Care and treatment, Glioblastomas -- Care and treatment, Media executives, Cancer, Brain cancer, Gliomas, Business, general
Abstract

GREENWICH, Conn. (PRWEB) April 02, 2019 OncoSynergy, Inc., a patient-focused oncology company committed to advancing therapeutics to address dire unmet medical needs, announced today that the U.S. Food and Drug [...]

Published
2019

26. MRI Interventions Congratulates Dr. Clark Chen On First Patient Dosing In Minnesota For Phase 2 Glioblastoma Trial

Subjects
Product development, Navigation systems -- Product development, Clinical trials, Magnetic resonance imaging, Glioblastomas -- Care and treatment, Diagnostic imaging, Engineers, Scientists, Surgery, Genes, Neurosurgery, Gliomas, Time to market, General interest, News, opinion and commentary
Abstract

California: MRI Interventions, Inc. has issued the following press release: MRI Interventions, Inc. (OTCQB:MRIC), a platform neurosurgery company developing products designed for navigation, ablation, deep brain stimulation, biopsy, aspiration and [...]

Published
2019

27. MRI Interventions Congratulates Dr. Clark Chen On First Patient Dosing In Minnesota For Phase 2 Glioblastoma Trial

Subjects
Product development, Navigation systems -- Product development, Clinical trials, Magnetic resonance imaging, Glioblastomas -- Care and treatment, Diagnostic imaging, Engineers, Scientists, Surgery, Genes, Neurosurgery, Gliomas, Time to market, Banking, finance and accounting industries, Business
Abstract

IRVINE, Mar 25, 2019 (GLOBE NEWSWIRE via COMTEX) -- MRI Interventions, Inc. (OTCQB:MRIC), a platform neurosurgery company developing products designed for navigation, ablation, deep brain stimulation, biopsy, aspiration and gene [...]

Published
2019

28. OncoSynergy Announces Submission of IND Application for OS2966 in the Treatment of Glioblastoma

Subjects
United States. Food and Drug Administration, Medical research, Clinical trials, Glioblastomas -- Care and treatment, Cancer treatment, Antibodies, Gliomas, Immunotherapy, Orphan drugs, Telecommunications industry
Abstract

(PRWeb) - OncoSynergy, a venture-backed oncology company launched from UCSF and the JLABS South San Francisco incubator, announced that it has submitted an Investigational New Drug (IND) application with the [...]

Published
2019

29. OncoSynergy Announces Submission of IND Application for OS2966 in the Treatment of Glioblastoma

Subjects
United States. Food and Drug Administration, Medical research, Clinical trials, Glioblastomas -- Care and treatment, Cancer treatment, Antibodies, Gliomas, Immunotherapy, Orphan drugs, Business, general
Abstract

GREENWICH, Conn. (PRWEB) February 26, 2019 OncoSynergy, a venture-backed oncology company launched from UCSF and the JLABS South San Francisco incubator, announced that it has submitted an Investigational New Drug [...]

Published
2019

30. OncoSynergy Announces Submission of IND Application for OS2966 in the Treatment of Glioblastoma

Subjects
United States. Food and Drug Administration, Clinical trials, Cancer treatment, Medical research, Brain tumors -- Care and treatment, Glioblastomas -- Care and treatment, Brain cancer, Gliomas, Antibodies, Orphan drugs, Business, News, opinion and commentary
Abstract

OncoSynergy announced that it has submitted an FDA application for a first-in-human trial of its Orphan Drug designated experimental therapeutic OS2966 for malignant brain cancer. GREENWICH, Conn., Feb. 26, 2019 [...]

Published
2019

31. Zai Lab: China NMPA Approves Optun for the Treatment of Newly Diagnosed and Recurrent Glioblastoma

Subjects
Zai Lab Ltd., Cancer treatment, Alternating electric field therapy, Pharmaceutical industry, Glioblastomas -- Care and treatment, Chemotherapy, Gliomas, Cancer, Clinical trials, Tumors, Business, Business, international, Optune (Medical instrument)
Abstract

SHANGHAI and ST. HELIER, Jersey, May 13 -- Zai Lab Limited issued the following news release: - Optune is the first innovative treatment for glioblastoma approved in China in over [...]

Published
2020

32. UH treats its 1st glioblastoma patient with genetically modified poliovirus

Subjects
Hospitals, Vaccines, Genetically modified organisms, Cancer patients -- Care and treatment, Brain tumors -- Care and treatment, Glioblastomas -- Care and treatment, Periodicals, Gliomas, Cancer, Clinical trials, Tumors, Editors, Health
Abstract

2020 FEB 12 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- CLEVELAND-- University Hospitals (UH) Seidman Cancer Center treated its first patient in a new clinical [...]

Published
2020

33. AIVITA Biomedical Enrolls First Patient in Phase 2 Glioblastoma Trial

Subjects
Clinical trials, Immunotherapy, Stem cells, Brain tumors -- Care and treatment, Glioblastomas -- Care and treatment, General interest, News, opinion and commentary
Abstract

IRVINE: AIVITA Biomedical, Inc. has issued the following press release: AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today the enrollment of its first patient [...]

Published
2018

34. Istari Oncology Announces New England Journal of Medicine Publication of Phase 1 Trial Results in Patients with Recurrent Glioblastoma Treated with PVSRIPO

Subjects
United States. Food and Drug Administration, Clinical trials, Periodical publishing -- Product development, Cancer research, Recurrence (Disease) -- Care and treatment, Immunotherapy, Glioblastomas -- Care and treatment, Business, Business, international
Abstract

* 21% Overall Survival at 24 Months and 36 Months, Compared to 14% and 4% in Matched Historical Controls * PVSRIPO Granted Breakthrough Status and Orphan Status from the US [...]

Published
2018

35. NWBio Announces Scientific Publication of Interim Survival Data From Phase 3 Trial of DCVax(r)-L for Glioblastoma Brain Cancer

Subjects
Clinical trials, Brain cancer -- Care and treatment, Glioblastomas -- Care and treatment, General interest, News, opinion and commentary
Abstract

BETHESDA: Northwest Biotherapeutics has issued the following press release: - Northwest Biotherapeutics (OTCQB: NWBO) -- ('NW Bio'), a biotechnology company developing DCVax(r) personalized immune therapies for solid tumor cancers, announced [...]

Published
2018

37. CANbridge Receives Approval to Commence CAN008 Phase II|III Trial in Glioblastoma Multiforme (GBM) in China

Subjects
Clinical trials, Radiotherapy, Drug approval, Glioblastomas -- Care and treatment, General interest, News, opinion and commentary
Abstract

BEIJING, China: CANbridge Life Sciences, Ltd. has issued the following press release: CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, announced [...]

Published
2018

39. Researchers at Sarah Cannon Research Institute Have Reported New Data on Solid Cancer [Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma ...]

Subjects
Novartis Pharmaceuticals Corp. -- Product development, Clinical trials, Cancer -- Care and treatment, Bevacizumab -- Product development, Cancer research, Pharmaceutical industry -- Product development, Glioblastomas -- Care and treatment, Recurrence (Disease), Gliomas, Antineoplastic agents, Medical research, Tumors, Editors, Health
Abstract

2019 AUG 26 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators discuss new findings in Oncology - Solid Cancer. According to news reporting from [...]

Published
2019

40. Basilea announces clinical study agreement with Adult Brain Tumor Consortium to explore BAL101553 in newly diagnosed glioblastoma

Subjects
United States. National Cancer Institute, Clinical trials, Brain, Cancer -- Care and treatment, Ionizing radiation, Brain tumors -- Care and treatment, Glioblastomas -- Care and treatment, Business, international, American Association for Cancer Research
Abstract

(GLOBE NEWSWIRE via COMTEX) -- Basilea Pharmaceutica AG / Basilea announces clinical study agreement with Adult Brain Tumor Consortium to explore BAL101553 in newly diagnosed glioblastoma . Processed and transmitted [...]

Published
2017

41. Inovio & Regeneron Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy

Subjects
Regeneron Pharmaceuticals Inc., Clinical trials, Immunotherapy, Pharmaceutical industry, Glioblastomas -- Care and treatment, T cells, General interest, News, opinion and commentary
Abstract

California: Inovio Pharmaceuticals Inc has issued the following press release: Inovio Pharmaceuticals, Inc. (NASDAQ:INO) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced a clinical study agreement for a phase 1b/2a immuno-oncology [...]

Published
2017

42. United States : Regeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy

Subjects
Regeneron Pharmaceuticals Inc., Clinical trials, Immunotherapy, Pharmaceutical industry, Glioblastomas -- Care and treatment, T cells, Business, international
Abstract

Regeneron Pharmaceuticals, Inc and Inovio Pharmaceuticals, Inc today announced a clinical study agreement for a Phase 1b/2a immuno-oncology trial. The study will be conducted by Inovio in patients with newly-diagnosed [...]

Published
2017

43. Bristol-Myers Squibb Announces Results from CheckMate -143, a Phase 3 Study of Opdivo (nivolumab) in Patients with Glioblastoma Multiforme

Subjects
Bristol-Myers Squibb Co. -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Glioblastomas -- Care and treatment, General interest, News, opinion and commentary, Opdivo (Medication)
Abstract

PRINCETON: Bristol-Myers Squibb Company has issued the following news release: Bristol-Myers Squibb Company (NYSE:BMY) today announced that CheckMate -143, a randomized Phase 3 clinical trial evaluating the efficacy and safety [...]

Published
2017

44. Medicenna Treats First Patient in Phase 2b Recurrent Glioblastoma Trial

Subjects
Clinical trials, Glioblastomas -- Care and treatment, General interest, News, opinion and commentary
Abstract

Toronto: Medicenna Therapeutics Corp has issued the following news release: Medicenna BioPharma Inc. ('Medicenna' or 'the Company'), a wholly owned subsidiary of Medicenna Therapeutics Corp., a publicly listed clinical stage [...]

Published
2017

45. United States : Bristol-Myers Squibb Announces Results from CheckMate -143, a Phase 3 Study of Opdivo (nivolumab) in Patients with Glioblastoma Multiforme

Subjects
Bristol-Myers Squibb Co. -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Glioblastomas -- Care and treatment, Business, international, Opdivo (Medication)
Abstract

Bristol-Myers Squibb Company today announced that CheckMate -143, a randomized Phase 3 clinical trial evaluating the efficacy and safety of Opdivo in patients with first recurrence of glioblastoma multiforme (GBM), [...]

Published
2017

46. Bristol-Myers Squibb Announces Results from CheckMate -143, a Phase 3 Study of Opdivo (nivolumab) in Patients with Glioblastoma Multiforme

Subjects
Bristol-Myers Squibb Co. -- Product development, Ono Pharmaceutical Company Ltd. -- Product development, Clinical trials, Activities of daily living, Pharmaceutical industry -- Product development, Glioblastomas -- Care and treatment, Business, Business, international, Yervoy (Medication), Opdivo (Medication)
Abstract

PRINCETON, N.J. -- Bristol-Myers Squibb Company (NYSE:BMY) today announced that CheckMate -143, a randomized Phase 3 clinical trial evaluating the efficacy and safety of Opdivo in patients with first recurrence [...]

Published
2017

47. BERG Initiates Phase I/II Monotherapy Trial of BPM 31510-IV in Patients with Glioblastoma Multiforme (GBM)

Subjects
Clinical trials, Business performance management, Medical research, Glioblastomas -- Care and treatment, Business, News, opinion and commentary
Abstract

BOSTON, Feb. 15, 2017 /PRNewswire/ --®BERG LLC, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced that it has initiated a Phase I/II monotherapy clinical [...]

Published
2017

48. Data on Glioblastomas Detailed by Researchers at Cleveland Clinic (Phase I Trial of Radiosurgery Dose Escalation Plus Bevacizumab in Patients With Recurrent/Progressive Glioblastoma)

Subjects
Surgery, Radiosurgery, Clinical trials, Bevacizumab -- Product development, Glioblastomas -- Care and treatment, Angiogenesis inhibitors, Radiotherapy, Antineoplastic agents, Gliomas, Technology, Editors, Medical equipment, Health, Health care industry, Cleveland Clinic
Abstract

2019 JAN 27 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Devices & Surgical Technology Week -- Researchers detail new data in Oncology - Glioblastomas. According to news [...]

Published
2019

49. Bortezomib Sensitization of Recurrent Glioblastoma With Unmethylated MGMT Promoter to Temozolomide Phase 1B/II Study

Subjects
Clinical trials, Bortezomib -- Product development, Temozolomide -- Product development, Glioblastomas -- Care and treatment, Health, Psychology and mental health
Abstract

2018 SEP 3 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- Staff editors report on the newly launched clinical trial, NCT03643549, which has the [...]

Published
2018

50. Patient Enrollment Underway in Phase 2 Trial for Recurrent Glioblastoma Multiforme

Subjects
Clinical trials, Cancer treatment, Glioblastomas -- Care and treatment, Chemistry
Abstract

M2 PHARMA-June 28, 2018-Patient Enrollment Underway in Phase 2 Trial for Recurrent Glioblastoma Multiforme (C)2018 M2 COMMUNICATIONS - Vancouver, Canada-based cancer therapies developer DelMar Pharmaceuticals (NASDAQ: DMPI) has updated patient [...]

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results